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Introduction: This study aimed to assess the utility of musculoskeletal ultrasound (MSUS) in patients with joint
symptoms using a probabilistic approach.
Methods: One hundred and three patients without prior rheumatologic diagnosis and referred to our clinic for
evaluation of inflammatory arthritis were included. Patients were assessed clinically including joint examination,
laboratory testing including acute-phase reactants, rheumatoid factor (RF) and anti citrulinated protein antibody
(ACPA), and radiographs of hands and feet if clinically indicated. A diagnostic assessment was then performed by
the responsible rheumatologist where the probability of a) any inflammatory arthritis and b) rheumatoid arthritis
was given on a 5-point scale ranging from 0 to 20% up to 80 to 100% probability. Subsequently, an ultrasound
examination of the wrist, metacarpophalangeal (MCP), proximal interphalangeal (PIP) joints 2 to 5 in both hands,
metatarsophalangeal (MTP) joints 2 to 5 in both feet and any symptomatic joints was performed and the results
presented to the same rheumatologist. The latter then assessed the diagnostic probabilities again, using the
same scale.
Results: The rheumatologists’ certainty for presence/absence of inflammatory arthritis and rheumatoid arthritis was
increased significantly following ultrasound performance. The proportion of patient for whom diagnostic certainty
for inflammatory arthritis was maximal was 33.0% before and 71.8% after musculoskeletal ultrasound (P <0.001).
With regard to a diagnosis of RA, the proportions were 31.1% pre-test and 61.2% post-test (P <0.001). MSUS findings
agreed with the final diagnosis in 95% of patients.
Conclusion: Musculoskeletal ultrasound, when added to routine rheumatologic investigation, greatly increases the
diagnostic certainty in patients referred for the evaluation of inflammatory arthritis. The changes from pre-test to
post-test probability quantify the diagnostic utility of musculoskeletal ultrasound in probabilistic terms.Introduction
Musculoskeletal complaints are exceedingly common in
the population and a large proportion of patients with
severe, refractory, or unclear joint symptoms are referred
to rheumatology units for further diagnostic evaluation.
The traditional evaluation of patients with joint symp-
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stated.examination, complemented by blood tests including
rheumatoid factor (RF) and anti-citrullinated protein anti-
body (ACPA), synovial fluid examination, and radiography
of the affected joints [1,2]. Although the traditional
methods are well-established, there are still a sizeable
proportion of patients in this category who are not reliably
diagnosed in the early stages of the disease [3].
Musculoskeletal ultrasound (MSUS) is a reliable, cost
effective, patient-friendly and safe imaging modality used
as a complement to other diagnostic methods in rheuma-
tology [4-6]. MSUS has been shown to be superior to
clinical examination to identify synovitis [7-10] and
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clinical management of rheumatoid arthritis (RA), when
there is diagnostic doubt, MSUS can be used to improve
the certainty of diagnosis above clinical signs and symp-
toms alone [11]. Although gray-scale MSUS does have an
important role to play in synovitis identification, color or
power Doppler imaging are more beneficial in identifying
active inflammation by detecting hypervascularisation and
hyperemia in synovial inflammation [12].
Quantitative analyses of the diagnostic utility of MSUS
in patients with arthritis in rheumatologic practice have
been done in smaller groups of patients [3,13-15]. A
study by Matsos et al. showed that synovitis in the
hands and feet detected by MSUS improved the cer-
tainty of a diagnosis of seronegative arthritis and signifi-
cantly influenced the rheumatologist’s confidence in the
management plan [15]. Freeston et al. reported that in
patients with arthritis of unknown etiology, combining
power Doppler ultrasound (PDUS) with conventional
assessment can help rheumatologists to achieve a higher
certainty of diagnosis [3]. In contrast, a recent study
based on a retrospective analysis of clinical datasets
from an early arthritis cohort in the UK showed that
MSUS provided no additional discriminatory value to
predict persistent inflammatory arthritis [16]. Nonethe-
less, EULAR has recommended the use of MSUS in this
setting [11].
To define the diagnostic utility of a test, two funda-
mentally different approaches can be taken. In a classical
(deterministic) analysis, the performance of the test is
measured against a gold standard, leading to value for
sensitivity, specificity, and positive and negative pre-
dictive value. This type of analysis makes the underlying
assumption that a diagnosis is either present or absent,
that it is an all-or-none phenomenon. In clinical prac-
tice, this is not necessarily the case, and clinicians asses-
sing patients with early arthritis often have to express
their diagnosis as probabilities. Therefore, in the other
alternative, a probabilistic (Bayesian) analysis, one ac-
cepts that there is a range of diagnostic uncertainties or
certainties, from highly unlikely to highly likely, and as-
sesses the degree to which the addition of a test changes
the diagnostic certainty. This study aimed to assess the
diagnostic impact of MSUS findings in patients referred
for rheumatologic evaluation because of suspected inflam-
matory arthritis primarily using a probabilistic approach.
Methods
Patients and clinical assessment
Patients in this study were recruited consecutively bet-
ween 2010 and 2013. All patients had suspected inflam-
matory arthritis but had no prior rheumatologic diagnosis.
They reported inflammatory symptoms, mostly from the
hands and feet, such as arthralgia, stiffness and swollenjoints. All patients had been referred by general practi-
tioners to the early arthritis clinic. As is always done, a
first clinical assessment was performed by a rheumato-
logist, based on medical history, physical examination, and
review of previously performed laboratory and/or radio-
logical studies. The assessment was usually complemented
by new blood tests including anti-citrullinated protein
antibody (ACPA), rheumatoid factor (RF) and/or acute
phase reactants. Radiographic assessment of the hands
and feet was also performed. No MSUS assessment was
done at this time point. The patients were invited to par-
ticipate in the study and after informed consent was given,
the rheumatologist completed the study case-report form
(CRF) which included her/his assessment of the likelihood
that the patient had: a) inflammatory arthritis; b) RA. In
this pre-test assessment, the physician based likelihood on
all available clinical and laboratory data but without
any MSUS information on a five-point scale: very likely
(≥80%), likely (≥60% and <80%), possible (≥40% and <60%),
not likely but possible (≥20% and <40%) and very unlikely
(<20%).
Importantly, in some analyses we considered patients
with the highest and lowest degrees of diagnostic likeli-
hood as one group, representing the group of highest
diagnostic certainty. Thus, we included those patients
where the diagnosis was ≥80% likely and those where
the diagnosis was <20% likely, because both of these
groups represented a high degree of confidence on the
part of the clinician regarding the diagnosis, contrasting
with those patients where the diagnosis was 40% to
60% likely and who represented the greatest diagnostic
uncertainty.
Subsequently MSUS was performed by one sono-
rheumatologist (HR) and the results, given descriptively
as morphological and vascularization data of the studied
joints were presented for post-test assessment to the
same rheumatologist who had performed the pre-test
evaluation. The latter then assessed the diagnostic pro-
babilities again, using the same five-point scale. In the
present study, there were four rheumatologists in total
who met the patients from the beginning and performed
the pre-test and post-test assessment on a five-point
scale. As an additional control, the participating patients’
cases were described as vignettes, once without and once
with the results of the MSUS examination. These
vignettes were then scored by another rheumatologist in
random order, again using a probabilistic approach.
We also analyzed the utility of MSUS in classical terms,
based on the final diagnosis that was obtained for each pa-
tient by the same rheumatologist who did the pre-test and
post-test evaluation. The predictive accuracy of MSUS
was assessed when every patient had final diagnosis at the
end of the follow-up time that was one year after inclusion
of the last patient. In general, RA was diagnosed if 1987
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criteria [17] or 2010 ACR/EULAR classification criteria
[1] were fulfilled. Psoriatic arthritis (PsA) was diagnosed
based on clinical judgment, performed by the rheumatolo-
gist and not necessarily based on classification criteria.
Undifferentiated inflammatory arthritis (UIA) was diag-
nosed when arthritis was confirmed but classification
criteria for a specific rheumatologic disease were not ful-
filled. These diagnoses were re-analyzed one year after in-
clusion of the last patient. We also studied the treatments
that the patients had been given during a follow up of 1 to
4 years. This study was approved by Regional Ethical
Review Board in Stockholm. All participants gave written
informed consent before inclusion.
Musculoskeletal ultrasound assessment
MSUS, including B-mode and color Doppler ultrasound
(CDUS) was performed by one sono-rheumatologist
(HR), who had 6 years experience of performing/reading
MSUS. The MSUS findings were presented to the four
rheumatologists as a report in the patient’s journal, of
joints and/or tendons with thickened synovium with or
without Doppler activity. The findings were interpreted
as active synovitis/tenosynovitis (Doppler-positive) or
signs of prior synovitis/tenosynovitis (Doppler-negative
thickening) in four categories: arthritis certain (one or
more joints with hyperemia in synovial hypertrophy);
arthritis very likely (two or more joints with Doppler-Figure 1 Semiquantitative ultrasound score in B-mode at the wrist jo
Doppler semiquantitative ultrasound at the metacarpophalangeal (M
musculoskeletal ultrasound finding was grade one in both B-mode and conegative synovial hypertrophy or two with tenosynovitis
or one Doppler-negative synovial hypertrophy and one
with tenosynovitis); arthritis possible (one joint with
Doppler-negative synovial hypertrophy or one with
tenosynovitis) and arthritis unlikely (normal ultrasound
findings). The categorization was only performed in
order to investigate the reliabiliy of MSUS evaluation
performed by the sono-rheumatologist. We compared
the MSUS findings with the final diagnosis and the num-
ber of patients with anti-rheumatic treatment at the end
of the follow-up time. MSUS findings were categorized
as positive or negative findings in B-mode and CDUS
and the cut off was grade 1 for definition of positive
signs in both B-mode and CDUS (Figure 1) according to
the scoring system by Ohrndorf et al. [18]. The General
Electric LOGIQ E9 unit (Wauwatosa, WI, USA) with a
linear array transducer was used for this study. The
B-mode frequency was 15 MHz. The CDUS setting was as
follows: frequency of 10 MHz, pulse repetition frequency
of 0.5 KHz, and wall filter of 69 Hz. The MSUS examin-
ation was divided in two parts: a) mandatory joints b)
symptomatic joints. Bilateral wrist (including radiocarpal
and midcarpal), metacarpophalangeal (MCP) joints, prox-
imal interphalangeal (PIP) joints, flexor tendons in the
second to fifth fingers and metatarsophalangeal (MTP)
joints 2 to 5 in the feet were scanned in all the patients as
mandatory joints. Scanning of the wrist included central,
radial and ulnar dorsal longitudinal positions. Volarint in the central dorsal longitudinal position (A) and color
CP) joints in the dorsal longitudinal position (B). Cut off for positive
lor Doppler ultrasound in this study.
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pected flexor tenosynovitis in this area. MCP and MTP
joints 2 to 5 were scanned with dorsal and PIP joints 2 to
5 with the volar longitudinal position. For symptomatic
joints, if the patients reported symptoms from joints other
than the above, the sono-rheumatologist scanned these
symptomatic joints at the same time in order to see if
there were any sonographic changes for synovitis, teno-
synovitis, tendinitis/enthesitis or bursitis in these areas,
both in B-mode and CDUS.
Statistical analysis
Normally distributed measures were presented as mean
(SD) group differences and were analyzed with Student’s
t-test. Changes in proportions from pre-test to post-test
were analyzed by the McNemar test. Differences in
proportions between groups were analyzed with Fisher’s
exact test or the chi-square test. A marginal homo-
geneity model for repeated measures was used for
analyzing the change in diagnosis in association with
ultrasound findings.
Results
Patient characteristics and ultimate diagnosis
One hundred and three patients with a mean age (SD)
of 50 (16.4) years were included consecutively in this
study. The proportion of patients with ACPA and RF
positivity was 29% and 34%, respectively. The mean (SD)
symptom duration was 8.5 (3.8) months: 76 patients
(73.8%) were female.
At the end of the follow-up time, 65% (67/103) of
patients were diagnosed as having any inflammatory
arthritis, while the remainder did not receive a specific
rheumatologic diagnosis: 36.9% (38/103) of patients were
diagnosed as having RA; 21.4% (22/103) had UIA; 5
patients were diagnosed with PsA, one with polymyositis,
and one with gout. Patients who were found to have no
rheumatologic disease were referred back to the general
practitioner; a review of data in the Swedish Rheumatology
Quality registry (SRQ) at the end of the follow-up time
showed that no one in this group had been referred to the
rheumatology departments again during the study period.
At the end of follow up, 53.4% of the original cohort
(55/103) had been given disease-modifying anti-rheumatic
drugs (DMARDs) of whom 35 were treated with metho-
trexate (MTX) and 14 had other DMARDs. Eighteen
patients were treated with biologics as monotherapy or in
combination with DMARDs.
Impact of MSUS on diagnostic likelihood at first
assessment of early arthritis
MSUS assessment showed that 63.1% (65/103) of pa-
tients had ultrasound findings in B-mode and 58.3%
(60/103) in CDUS, indicating inflammatory arthritis.With regard to the clinical likelihood of having (any)
inflammatory arthritis, the proportion of patients for
whom diagnostic certainty was maximal (those with <20%
and ≥80% likelihood) was 34/103 (33.0%) before MSUS
and 74/103 (71.8%) after MSUS (McNemar test P-value
<0.001). With regard to the probability of RA, the propor-
tions were 32/103 (31.1%) pre-MSUS and 63/103 (61.2%)
post-MSUS (McNemar test P -value <0.001). Parallel
reductions were seen in the proportions of patients with
greatest diagnostic uncertainty (40% to 60% likelihood),
from 30/103 (29.1%) to 10/103 (9.7%) (McNemar test
P-value = 0.06) for diagnosis of (any) inflammatory joint
disease and from 26/103 (25.2%) to 8/103 (7.8%) (McNemar
test P-value = 0.08) for diagnosis of RA, respectively.
Figure 2 demonstrates the impact of MSUS information
when it was presented to the rheumatologist for post-test
assessment showing how the two groups with the highest
and lowest likelihood score increased and how the middle
group decreased. As shown, 27 patients moved toward
lesser likelihood for inflammatory arthritis and 39 moved
toward higher likelihood. The logistic linear model also
showed a significant association between MSUS findings
and change in diagnostic certainty for any inflammatory
arthritis and for RA (P <0.0001). When the cases were
re-scored by another independent rheumatologist based
on case vignettes without and with MSUS, nearly identical
results were obtained as in the original scoring (data not
shown).
Relationship between MSUS at first evaluation and
ultimate diagnosis
Overall, of the patients who were included in the study
65% were diagnosed with any inflammatory arthritis and
36.9% with RA. Figure 3 demonstrates the final diagnosis
in the groups categorized by pre-test and post-test like-
lihoods and how these initial risks changed within the
groups to higher or lower risks in post-test evaluation.
As shown, the rheumatologists’ pre-MSUS evaluation
was significantly less accurate when compared to the
final diagnosis, and was particularly wanting in being
able to identify with confidence those patients without
inflammatory arthritis.
With regard to the final rheumatologic diagnosis and
accuracy of MSUS to establish the diagnosis inflam-
matory arthritis or not, based on positive and negative
findings, Figure 4A demonstrates the impact of MSUS
on both confirming and denying the presence of arth-
ritis. In the vast majority (>95%) of patients, there was
agreement between the MSUS findings and final diag-
nosis. A similar result was obtained when the accuracy
of MSUS was investigated in terms of the number of
patients on anti-rheumatic treatment at the end of the
follow-up time, as shown in Figure 4B. The proportion
of patients for whom diagnostic certainty was more than
Figure 2 Likelihood for inflammatory arthritis. (A) Pre-test and (B) post-test likelihood for presence of inflammatory arthritis.
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therapy (DMARDs, biologics and corticosteroids) was
23/103 (22.0%) before MSUS and 48/103 (46.6%) after
MSUS (McNemar test P-value <0.001). As shown in
Figure 5B, when the post-test likelihood for inflam-
matory arthritis was below 40% there was no prescrip-
tion of anti-rheumatic treatment, which demonstrated
the practical consequence of using MSUS. However
when the pre-test diagnostic certainty was below 40%, the
patients were very unlikely to be prescribed anti-rheumatic
therapy (2 of 28 patients, as shown in Figure 5A). The data
for anti-rheumatic treatment were also checked in the pa-
tients’ journals one year after inclusion of the last patient.
The decision to treat patients with anti-rheumatic therapy,
including DMARDs, biologics and corticosteroids, was
made after knowing the ultrasound results.Figure 3 Proportion of patients with a different final diagnosis in pre
arthritis. The percentages above the columns show the fraction of inflammDiscussion
In this study, we addressed the diagnostic utility and bene-
fit of MSUS when added to the conventional rheuma-
tologic diagnostic assessment in patients with suspected
inflammatory arthritis, using a probabilistic approach.
Thus, the core of the paper was the difference between
pre-test and post-test assessments of diagnostic uncer-
tainty or certainty, and we demonstrated a marked impact
of MSUS findings upon the rheumatologist’s evaluation of
likelihood of any inflammatory arthritis in general and for
RA specifically. The results also indicate that our rheuma-
tologists have learned to use MSUS in the diagnosis of
early inflammatory arthritis. We found that MSUS greatly
increased the diagnostic certainty for diagnosis of inflam-
matory arthritis in general and for RA in particular, which
is consistent with a previous study by Matsos et al. [15].-test (A) and post-test (B) evaluation of likelihood of inflammatory
atory arthritis within each column. RA, rheumatoid arthritis.
Figure 4 Proportion of patients with three final diagnosis (A) and ongoing anti-rheumatic treatment at the end of the follow up time
(B) in four categories with different degrees of musculoskeletal ultrasound diagnostic certainty. RA, rheumatoid arthritis.
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certainty (≥80% certain of diagnosis) and the negative
diagnostic certainty (<20% likely to have the diagnosis),
while greatly reducing the number of patients where diag-
nostic uncertainty was maximal. These findings provide
quantitative support for the utility of MSUS in the
evaluation of patients with suspected arthritis when there
is diagnostic doubt, as also supported by the EULAR
recommendation for the use of imaging of the joints in
the management of RA [11]. As expected, among patients
with early arthritis symptoms the likelihood of having any
inflammatory arthritis, and especially of having RA, in-
creased with the presence of MSUS findings. In addition,
we found that MSUS also improved diagnostic accuracy
compared to clinical assessment alone, when analyzed in a
classical (deterministic) manner; as also shown previously
in >95% of patients there was agreement between MSUS
findings and the final diagnosis.
In the study by Matsos et al. [15], 62 patients were re-
ferred by two rheumatologists for MSUS scanning of theFigure 5 Proportion of patients on anti-rheumatic therapy, including
post-test (B) evaluation of likelihood for inflammatory arthritis. RA, rhhands and feet and the diagnostic confidence for diagnosis
was made before and after MSUS evaluation. In that
study, the rheumatologist’s certainty for seronegative
arthritis was significantly increased (46.8% versus 61.3%,
P = 0.05) but no significant increase in diagnostic certainty
for RA was observed (46.8% versus 61.3%, P = 0.17). Our
results for increased diagnostic certainty of RA were highly
significant (31.1% versus 61.2%, P <0.001). McNemar's test
was performed in both studies to determine differences in
pre-test test and post-test diagnostic probability. In the
study by Matsos et al., only joints requested by the
rheumatologists were scanned rather than a pre-specified
number of joints in the hands and feet as in our study.
Freeston et al. analyzed the predictive value of MSUS
in the diagnosis of inflammatory arthritis in 50 ACPA-
and RF-negative patients with significant diagnostic
uncertainty. In that study, positive MSUS findings in-
creased the probability of inflammatory arthritis from
between 2% and 30% to between 50% and 94% [3]. In
the present study, we observed that MSUS results (bothDMARDs, corticosteroids and biologics in pre-test (A) and
eumatoid arthritis.
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tainty from 33% to 71.8% for any inflammatory arthritis.
Theoretically this might have less to do with the patient’s
final diagnosis and more with the rheumatologist’s
certainty on post-test evaluation. However, as shown in
Figure 3, the diagnosis of patients with inflammatory arth-
ritis in general and RA specifically as the final diagnosis,
moved to greater certainty on post-test evaluation. In
our study, increase in diagnostic certainty was observed
in both ACPA/RF- positive and -negative patients.
A recent retrospective study by Pratt et al. showed
that MSUS as a routine supplement in early arthritis
patients did not add any substantial discriminatory value
for predicting persistent inflammatory arthritis. Among
379 patients, seven clinical and serological variables had
independent and significant associations with persistent
arthritis. The risk metric for clinical and serological
variables was shown as having excellent discriminatory
ability (area under the curve = 0.91, P <0.001). Addition
of MSUS did not further improve predictive accuracy
and the diagnostic utility of the new metric was equiva-
lent to the previous one [16]. Our study showed that in
most of the patients MSUS had an excellent association
with higher diagnostic certainty. One key difference bet-
ween the two studies is the number of scanned joints,
which was 16 in that study and at least 26 in our study.
We performed MSUS of the wrist in three positions (as
described in Methods) while scanning of the wrist was
not performed in that study. Prior studies showed the
sensitivity value for scanning of the wrist in inflamma-
tory arthritis [14,19]. Another difference here is that we
had a prospective design and our focus was on whether
MSUS could influence and increase the diagnostic
certainty during the rheumatologic investigation. Our
focus in this study was not to evaluate the sensitivity
and specificity of MSUS in early arthritis as the validity
of MSUS for detecting synovitis has been confirmed by
several previous studies [4,7,9,10,20].
A study by Kelly et al. presented as an abstract at the
EULAR congress 2013 [21] showed that routine use of
MSUS for patients with suspected inflammatory arthritis
was associated with earlier diagnosis and earlier initiation
of therapy in patients with RA as the final diagnosis. In
that study, the patients were divided into two groups,
those who were diagnosed by MSUS versus those who
were not. A significantly greater proportion of patients in
the MSUS group received a final diagnosis at their first
visit and a similar difference was observed for patients
with a diagnosis of RA. Where patients had a diagnosis of
RA, there was a significant difference in the time to
diagnosis and time to initiation of therapy. The main
difference between our study and that study is that we
performed MSUS for all patients after the first visit. Our
study was not designed to show a difference betweenpatients having MSUS and those not having it. However our
result is consistent with that study and as shown in our
results, most of the patients with positive MSUS finding had
anti-rheumatic therapy at the end of the follow-up time.
Our study has limitations and perhaps the main one
was that the treating rheumatologist who performed the
scoring of diagnostic certainty/uncertainty after MSUS
was aware of her/his own scoring before MSUS and may
have felt motivated to improve the result. Moreover, pre-
test assessment was already done under the assumption
that more information (in this case MSUS results) would
be available at a later stage, which maybe lead to increased
post-test probability. However, when the cases were
re-scored by another independent rheumatologist on the
basis of vignettes, mixed up and in random order, nearly
identical results were obtained. Another limitation was
that the sono-rheumatologist was not completely blinded
and received summary information about patients before
MSUS, which could have influenced his judgment.
The strength of this study was the idea of using a
probabilistic approach to determine if MSUS improved
the diagnostic certainty on a five-point scale, which
indeed it did. A further strength of this study was that
MSUS could influence the rheumatologic judgment
during the investigation and finally the diagnosis. As
Ceponis et al. showed previously, MSUS of the hand
and wrist can increase the physicians’ confidence in their
clinical decisions [13] and we believe that our MSUS
results could also influence rheumatologists in their
decisions to make a diagnosis or to re-refer the patients.
We established that our rheumatologists became more
certain of the presence or absence of inflammatory arth-
ritis when they knew the MSUS findings. In other words,
we showed that the rheumatologists were influenced by
the ultrasound findings. Furthermore, they performed
well after being influenced. Ultrasound helped them
indentify with certainty more patients with and without
inflammatory arthritis, and most of the patients with
positive MSUS finding had anti-rheumatic treatment
(mostly DMARDs) at the end of the follow-up time.
Additionally, the utility of MSUS was most impressive
when diagnostic uncertainty was maximal, as might have
been anticipated. This is the group where a decision to
prescribe anti-rheumatic therapy is more difficult and
where ultrasound can be more useful by increasing diag-
nostic certainty on the presence/absence of inflamma-
tory arthritis. When the diagnosis became more certain
towards the positive end then the impact of MSUS
became somewhat less although we still observed a
numeric increase in the use of anti-rheumatic treatment.
Conclusion
MSUS, when added to routine clinical and laboratory
examinations, greatly increased the diagnostic certainty in
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arthritis. Moreover, inflammatory arthritis in general and
RA specifically were diagnosed with higher certainty based
on MSUS findings.
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